Alain Puisieux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7151657/publications.pdf

Version: 2024-02-01

		4	46918	20	0307
115	14,318		47		116
papers	citations	3	h-index		g-index
132	132		132		22017
all docs	docs citati	ons	times ranked		citing authors

#	Article	IF	CITATIONS
1	Metastasis: a question of life or death. Nature Reviews Cancer, 2006, 6, 449-458.	12.8	1,564
2	Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition. PLoS ONE, 2008, 3, e2888.	1.1	1,389
3	Guidelines and definitions for research on epithelial–mesenchymal transition. Nature Reviews Molecular Cell Biology, 2020, 21, 341-352.	16.1	1,195
4	Oncogenic roles of EMT-inducing transcription factors. Nature Cell Biology, 2014, 16, 488-494.	4.6	863
5	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 2008, 455, 967-970.	13.7	787
6	Induction of EMT by Twist Proteins as a Collateral Effect of Tumor-Promoting Inactivation of Premature Senescence. Cancer Cell, 2008, 14, 79-89.	7.7	633
7	Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. Cancer Research, 2009, 69, 2000-2009.	0.4	617
8	A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma. Cancer Cell, 2013, 24, 466-480.	7.7	450
9	p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, The, 1991, 338, 1356-1359.	6.3	436
10	Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nature Immunology, 2009, 10, 778-785.	7.0	415
11	Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway. Nature Genetics, 1996, 14, 482-486.	9.4	384
12	Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. Cancer Research, 2012, 72, 5188-5197.	0.4	285
13	Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnology, 2003, 3, 18.	1.7	281
14	p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer. Cancer Cell, 2013, 24, 318-330.	7.7	246
15	Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell, 2004, 6, 625-630.	7.7	238
16	Pleiotropic Roles for ZEB1 in Cancer. Cancer Research, 2018, 78, 30-35.	0.4	234
17	EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice. PLoS Genetics, 2012, 8, e1002723.	1.5	171
18	Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Reports, 2002, 3, 1055-1061.	2.0	158

#	Article	IF	Citations
19	A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability. Nature Medicine, 2017, 23, 568-578.	15.2	131
20	Retinoblastoma and p <i>53</i> tumor suppressor genes in human hepatoma cell lines. FASEB Journal, 1993, 7, 1407-1413.	0.2	123
21	Netrin-1 acts as a survival factor for aggressive neuroblastoma. Journal of Experimental Medicine, 2009, 206, 833-847.	4.2	118
22	Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clinical Cancer Research, 2016, 22, 5564-5573.	3.2	108
23	Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2016, 94, 450-460.	0.4	104
24	Inactivation of TIF1 \hat{I}^3 Cooperates with KrasG12D to Induce Cystic Tumors of the Pancreas. PLoS Genetics, 2009, 5, e1000575.	1.5	102
25	Copper isotope effect in serum of cancer patients. A pilot study. Metallomics, 2015, 7, 299-308.	1.0	99
26	Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene, 2003, 22, 1486-1490.	2.6	98
27	<scp>ZEB</scp> 1â€mediated melanoma cell plasticity enhances resistance to <scp>MAPK</scp> inhibitors. EMBO Molecular Medicine, 2016, 8, 1143-1161.	3.3	98
28	Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. International Journal of Cancer, 2002, 97, 439-445.	2.3	92
29	Neurofibromatosis typeÂ1 gene as a mutational target in a mismatch repair-deficient cell type. Human Genetics, 2003, 112, 117-123.	1.8	92
30	p53 as a target for anti-cancer drug development. Critical Reviews in Oncology/Hematology, 2006, 58, 190-207.	2.0	84
31	Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Research and Treatment, 2012, 132, 29-39.	1.1	83
32	BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. , 2000, 27, $57-64$.		81
33	Cellular Pliancy and the Multistep Process of Tumorigenesis. Cancer Cell, 2018, 33, 164-172.	7.7	79
34	Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Human Mutation, 2006, 27, 145-154.	1.1	77
35	The CD10 Enzyme Is a Key Player to Identify and Regulate Human Mammary Stem Cells. Stem Cells, 2010, 28, 1081-1088.	1.4	72
36	Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics, 2011, 6, 428-439.	1.3	70

#	Article	IF	CITATIONS
37	BTG2TIS21/PC3 induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene, 2002, 21, 6772-6778.	2.6	69
38	Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Human Mutation, 2007, 28, 1084-1090.	1.1	65
39	Cancer Stem Cells: The Emerging Challenge of Drug Targeting. Current Medicinal Chemistry, 2009, 16, 394-416.	1.2	64
40	$\langle i \rangle$ TWIST1 $\langle i \rangle$ Expression in Breast Cancer Cells Facilitates Bone Metastasis Formation. Journal of Bone and Mineral Research, 2014, 29, 1886-1899.	3.1	63
41	Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Research, 2002, 62, 3646-8.	0.4	63
42	TWIST1 a New Determinant of Epithelial to Mesenchymal Transition in EGFR Mutated Lung Adenocarcinoma. PLoS ONE, 2012, 7, e29954.	1.1	61
43	PLA2R1 Mediates Tumor Suppression by Activating JAK2. Cancer Research, 2013, 73, 6334-6345.	0.4	60
44	The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene, 2002, 282, 207-214.	1.0	57
45	Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. Nature Communications, 2020, 11, 3431.	5.8	57
46	A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Medicine, 2017, 15, 165.	2.3	56
47	Occurrence of Fragmentation of Free and Combined Forms of the β-Subunit of Human Chorionic Gonadotropin*. Endocrinology, 1990, 126, 687-694.	1.4	54
48	Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood, 2011, 117, 1673-1676.	0.6	51
49	Epithelial-mesenchymal transition transcription factors and miRNAs: "Plastic surgeons―of breast cancer. World Journal of Clinical Oncology, 2014, 5, 311.	0.9	50
50	BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood, 2008, 112, 3154-3163.	0.6	47
51	TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Letters, 2015, 357, 412-418.	3.2	44
52	C. elegans homologue of the Caf1 gene, which encodes a subunit of the CCR4-NOT complex, is essential for embryonic and larval development and for meiotic progression. Gene, 2005, 358, 73-81.	1.0	43
53	Snail Family Members Unequally Trigger EMT and Thereby Differ in Their Ability to Promote the Neoplastic Transformation of Mammary Epithelial Cells. PLoS ONE, 2014, 9, e92254.	1.1	43
54	Structural probing of human lutropin using antibodies raised against synthetic peptides constructed by classical and multiple antigen peptide system approaches. Molecular Immunology, 1990, 27, 363-368.	1.0	42

#	Article	IF	Citations
55	CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood, 2011, 118, 5130-5140.	0.6	42
56	Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Letters, 2005, 225, 111-120.	3.2	40
57	Ribosomal RNA 2′O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. NAR Cancer, 2020, 2, zcaa036.	1.6	40
58	Characterization of a cleavage product in the human choriogonadotropin \hat{l}^2 -subunit. Biochemical and Biophysical Research Communications, 1988, 154, 626-632.	1.0	39
59	Influence of neuroblastoma stage on serumâ€based detection of <i>MYCN</i> amplification. Pediatric Blood and Cancer, 2009, 53, 329-331.	0.8	35
60	Immunological and classical subtypes of oral premalignant lesions. Oncolmmunology, 2018, 7, e1496880.	2.1	35
61	ZEB1 transcription factor promotes immune escape in melanoma., 2022, 10, e003484.		35
62	Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Letters, 2005, 228, 91-96.	3.2	34
63	Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Molecular Cancer, 2008, 7, 50.	7.9	33
64	PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radical Biology and Medicine, 2013, 65, 969-977.	1.3	33
65	Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene, 2003, 22, 8956-8960.	2.6	32
66	Bromohydrin Pyrophosphate-stimulated Vγ9Π2 T Cells Expanded Ex Vivo From Patients With Poor-Prognosis Neuroblastoma Lyse Autologous Primary Tumor Cells. Journal of Immunotherapy, 2010, 33, 591-598.	1.2	32
67	Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis. Cancers, 2021, 13, 4561.	1.7	32
68	ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells. Molecular Cancer, 2014, 13, 213.	7.9	31
69	Circulating MYCN DNA Predicts MYCN-Amplification in Neuroblastoma. Journal of Clinical Oncology, 2005, 23, 8919-8920.	0.8	30
70	Sulfur isotope analysis by MC-ICP-MS and application to small medical samples. Journal of Analytical Atomic Spectrometry, 2016, 31, 1002-1011.	1.6	30
71	Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatric Blood and Cancer, 2011, 56, 757-761.	0.8	29
72	Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells. Journal of the American Chemical Society, 2022, 144, 11536-11545.	6.6	29

#	Article	lF	CITATIONS
73	Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. Human Mutation, 2002, 19, 108-113.	1.1	28
74	Variants in the Netrin-1 Receptor UNC5C Prevent Apoptosis and Increase Risk of Familial Colorectal Cancer. Gastroenterology, 2011, 141, 2039-2046.	0.6	28
75	Failsafe program escape and EMT: A deleterious partnership. Seminars in Cancer Biology, 2011, 21, 392-6.	4.3	28
76	TIF1 \hat{i}^3 Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability. Cancer Research, 2015, 75, 4335-4350.	0.4	27
77	Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene, 2000, 19, 2461-2464.	2.6	24
78	Gadd45a Activation Protects Melanoma Cells from Ultraviolet B-Induced Apoptosis. Journal of Investigative Dermatology, 2008, 128, 196-202.	0.3	24
79	Tif $\hat{\Pi}^3$ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (Cambridge), 2013, 140, 167-175.	1.2	24
80	Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. Oncotarget, 2017, 8, 2423-2436.	0.8	24
81	Mutational Targets in Colorectal Cancer Cells with Microsatellite Instability. Familial Cancer, 2006, 5, 29-34.	0.9	23
82	Intensityâ€dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. Genes Chromosomes and Cancer, 2011, 50, 178-185.	1.5	23
83	Influence of p53 and p21WAF1 expression on sensitivity of cancer cells to cladribine. Biochemical Pharmacology, 2003, 65, 121-129.	2.0	22
84	CDYL2 Epigenetically Regulates MIR124 to Control NF-κB/STAT3-Dependent Breast Cancer Cell Plasticity. IScience, 2020, 23, 101141.	1.9	22
85	EMT Transcription Factor ZEB1 Represses the Mutagenic POLÎ,-Mediated End-Joining Pathway in Breast Cancers. Cancer Research, 2021, 81, 1595-1606.	0.4	22
86	Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer, 2006, 6, 216.	1.1	21
87	Early origin of cancer metastases: Dissemination and evolution of premalignant cells. Cell Cycle, 2008, 7, 3659-3663.	1.3	21
88	The neurogene BTG2TIS21/PC3 is transactivated by \hat{l} Np73 \hat{l} ± via p53 specifically in neuroblastoma cells. Journal of Cell Science, 2005, 118, 1245-1253.	1.2	20
89	Deciphering the molecular mechanisms underlying the binding of the TWIST1/E12 complex to regulatory E-box sequences. Nucleic Acids Research, 2016, 44, 5470-5489.	6.5	20
90	Role of epithelial–mesenchymal transition factors in the histogenesis of uterine carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 85-94.	1.4	20

#	Article	IF	Citations
91	Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells. Nucleic Acids Research, 2015, 43, 5838-5854.	6.5	19
92	GermlinehMSH2andhMLH1 gene mutations in incomplete HNPCC families., 1997, 73, 831-836.		18
93	Is the KAI1 Metastasis Suppressor Gene a Cellular Target of p53? A Review of Current Evidence. Biochemical and Biophysical Research Communications, 2000, 278, 499-502.	1.0	16
94	Modulation of Oxidative Stress by Twist Oncoproteins. PLoS ONE, 2013, 8, e72490.	1.1	14
95	Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. Scientific Reports, 2018, 8, 7386.	1.6	12
96	Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. European Journal of Cancer, 2022, 169, 106-122.	1.3	12
97	Modulation of p36 gene expression in human neuronal cells. Journal of the Neurological Sciences, 1995, 128, 122-133.	0.3	11
98	A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. International Journal of Cancer, 2006, 119, 60-66.	2.3	10
99	UVB-Induced G2 Arrest of Human Melanocytes Involves Cdc2 Sequestration by Gadd45a in Nuclear Speckles. Cell Cycle, 2006, 5, 1859-1864.	1.3	10
100	Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer. BMC Cancer, 2022, 22, 526.	1.1	10
101	Upstream ORF affects MYCN translation depending on exon 1b alternative splicing. BMC Cancer, 2009, 9, 445.	1.1	8
102	Interhelical loops within the bHLH domain are determinant in maintaining TWIST1–DNA complexes. Journal of Biomolecular Structure and Dynamics, 2014, 32, 226-241.	2.0	8
103	Weekly administration of paclitaxel induces long-term aneugenicity in nude mice. Cancer Biology and Therapy, 2007, 6, 377-382.	1.5	7
104	The Heterodimeric TWIST1-E12 Complex Drives the Oncogenic Potential of TWIST1 in Human Mammary Epithelial Cells. Neoplasia, 2016, 18, 317-327.	2.3	7
105	p21Cip1 regulates cell–substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cells. European Journal of Cell Biology, 2011, 90, 631-641.	1.6	5
106	\hat{l}^2 III-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells. European Journal of Cell Biology, 2011, 90, 872-878.	1.6	5
107	Destabilization of the TWIST1/E12 complex dimerization following the R154P point-mutation of TWIST1: an in silico approach. BMC Structural Biology, 2018, 17, 6.	2.3	4
108	Role of EMT in the DNA damage response, doubleâ€strand break repair pathway choice and its implications in cancer treatment. Cancer Science, 2022, , .	1.7	4

ALAIN PUISIEUX

#	Article	IF	CITATIONS
109	Opposite Roles for ZEB1 and TMEJ in the Regulation of Breast Cancer Genome Stability. Frontiers in Cell and Developmental Biology, 2021, 9, 727429.	1.8	3
110	Quantifying local malignant adaptation in tissueâ€specific evolutionary trajectories by harnessing cancer's repeatability at the genetic level. Evolutionary Applications, 2019, 12, 1062-1075.	1.5	2
111	Article Commentary: Should We Consider Cancers as Embryonic Diseases or as Consequences of Stem-Cell Deregulation?. Clinical Medicine Oncology, 2008, 2, CMO.S603.	0.2	1
112	The cell-of-origin dictates the genomic landscape of breast cancers. Molecular and Cellular Oncology, 2017, 4, e1338931.	0.3	1
113	Assessing Cell Activities rather than Identities to Interpret Intra-Tumor Phenotypic Diversity and Its Dynamics. IScience, 2020, 23, 101061.	1.9	1
114	From where do Cancer-Initiating Cells Originate?. , 0, , .		1
115	Zeb1 expression by tumor or stromal cells is associated with spatial distribution patterns of CD8+ tumor-infiltrating lymphocytes: a hypothesis-generating study on 113 triple negative breast cancers. American Journal of Cancer Research, 2020, 10, 3370-3381.	1.4	1